2026-04-13T06:48:52Zhttps://recercat.cat/oai/requestoai:recercat.cat:2072/4747212025-07-29T22:47:02Zcom_2072_98col_2072_378192
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma : Results from the CALM Study
Waszczuk-Gajda, Anna
Penack, Olaf
Sbianchi, Giulia
Koster, Linda
Blaise, Didier
Reményi, Péter
Russell, Nigel
Ljungman, Per
Trneny, Marek
Mayer, Jiri
Iacobelli, Simona
Kobbe, Guido
Scheid, Christof
Apperley, Jane
Touzeau, Cyrille
Lenhoff, Stig
Jantunen, Esa
Anagnostopoulos, Achilles
Paris, Laura
Browne, Paul
Thieblemont, Catherine
Schaap, Nicolaas
Sierra, Jorge
Yakoub-Agha, Ibrahim
Garderet, Laurent
Styczynski, Jan
Schoemans, Helene
Moiseev, Ivan
Duarte, Rafael
Peric, Zinaida
Montoto, Silvia
van Biezen, Anja
Mikulska, Malgorzata
Aljurf, Mahmoud
Ruutu, Tapani
Kröger, Nicolaus
Morris, Curly Morris
Koenecke, Christian
Schoenland, Stefan
Basak, Grzegorz
Universitat Autònoma de Barcelona
Autologous stem cell transplantation in multiple myeloma
Complications
Multiple myeloma
Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short-and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0-100 days, 101 days-1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4-108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1-7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3-5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.
2022
Article
Journal of clinical medicine ; Vol. 11 Núm. 12 (6-2 2022), p. 3541
open access
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
https://creativecommons.org/licenses/by/4.0/